Mucosal healing and treatment efficacy in IBD

Inflammatory Bowel Disease Monitor

Volumn 10, Issue 2, 2009, Pages 35-42

  Van Assche, Gert ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955834934     PISSN: 14667401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Powell-Tuck J, Day DW, Buckell NA et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982;27:533-7. (Pubitemid 12120288)
2. Higgins PD, Schwartz M, Papili J et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis? Am J Gastroenterol 2005;100:355-61. (Pubitemid 40314520)
3. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
4. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-9.
5. Landi B, Anh TN, Cortot A et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992;102:1647-53.
6. Cellier C, Sahmoud T, Froguel E et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231-5. (Pubitemid 24092870)
7. Daperno M, D'Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004;60:505-12. (Pubitemid 39311530)
8. Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8. (Pubitemid 20095830)
9. Schnitzler F, Fidder H, Ferrante M et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301.
10. Sipponen T, Savilahti E, Kärkkäinen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14:1392-8.
11. Olaison G, Sjödahl R, Tagesson C. Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut 1990;31:325-8. (Pubitemid 20093672)
12. Frøslie KF, Jahnsen J, Moum BA et al.; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-22. (Pubitemid 47187355)
13. D'Haens G, Geboes K, Ponette E et al. Healing of severe recurrent ileitis with azathioprine therapy in patents with Crohn's disease. Gastroenterology 1997;112:1475-81. (Pubitemid 27181370)
14. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999;50:667-71. (Pubitemid 29518050)
15. Lémann M, Mary JY, Colombel JF et al.; Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005;128:1812-8. (Pubitemid 40824692)
16. Kozarek RA, Patterson DJ, Gelfand MD et al. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353-6.
17. van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
18. D'Haens G, van Deventer S, van Hogezand R et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999;116:1029-34. (Pubitemid 29203012)
19. Hanauer SB, Feagan BG, Lichtenstein GR et al.; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
20. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13. (Pubitemid 38182297)
21. Rutgeerts P, Diamond RH, Bala M et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42. (Pubitemid 43261469)
22. D'Haens G, Baert F, van Assche G et al.; Belgian Inflammatory Bowel Disease Reseach Group; North-Holland Gut Club. Early combined immunosuppresion or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371:660-7. (Pubitemid 351284485)
23. Colombel JF, Hébuterne X. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab pegol: first results of the MUSIC clinical trial. Am J Gastroenterol 2008;103:A1107 (Abstr.).
24. Sandborn WJ, Rutgeerts P, Reinisch W et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Am J Gastroenterology 2008;103:S436 (Abstr.).
25. Rutgeerts P, D'Haens G, Van Assche G. Adalimumab induces and maintains mucosal healing in patients with moderate to severe Crohn's disease. First results of the EXTEND trial. Gastroenterology 2009;136:A116 (Abstr.).
26. Carbonnel F, Gargouri D, Lémann M et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000;14:273-9. (Pubitemid 30145314)
27. Järnerot G, Hertervig E, Friis-Liby I et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805-11. (Pubitemid 40824691)
28. Ferrante M, Vermeire S, Katsanos KH et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 2007;13:123-8. (Pubitemid 46806219)
29. Treton X, Bouhnik Y, Mary JY et al.; Groupe D'Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID). Azatioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009;7:80-5.
30. Simrén M, Axelsson J, Gillberg R et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002;97:389-96. (Pubitemid 34160766)
31. Efthymiou A, Viazis N, Mantzaris G et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis 2008;14:1542-7.
32. Rutgeerts P, Geboes K, Vantrappen G et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63. (Pubitemid 20338451)